While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.

These are among the highest-yielding stocks on the S&P 500.

Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why ...

These companies are committed to rewarding shareholders.

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error. Here is what actually has to hold true for that ...

PFE remains a Buy for income-oriented investors, with the momentum reversal between established trading ranges likely ...

Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in ...

Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the ...

Pfizer is dealing with headwinds right now, but they aren't unusual headwinds in the pharmaceutical sector. The company is taking aggressive actions to get back on track and recently stated it plans ...

It's hard not to love high dividend yields. Who doesn't want more dividends for their money? Pfizer(NYSE: PFE) and its current yield of 7% will certainly grab your attention. But remember that the ...

The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of ...